Jaundice — Clinical Documentation Guide (2026)

🔍 Definition

Jaundice (icterus) is the yellow discoloration of the skin, sclerae, and mucous membranes caused by elevated serum bilirubin levels, generally becoming clinically visible when total serum bilirubin exceeds approximately 2–3 mg/dL in adults and 5 mg/dL in neonates. Bilirubin is a byproduct of heme catabolism: red blood cells are broken down, heme is oxidized to biliverdin and then reduced to unconjugated (indirect) bilirubin, which is bound to albumin and transported to the liver. There, hepatocytes conjugate bilirubin with glucuronic acid (via UGT1A1) to form water-soluble conjugated (direct) bilirubin, which is excreted into bile and ultimately eliminated in stool as urobilinogen (StatPearls — Jaundice).

Three broad pathophysiologic categories drive jaundice: (1) pre-hepatic (hemolytic) — excess bilirubin production overwhelms hepatic conjugation; (2) hepatic (hepatocellular) — impaired uptake, conjugation, or excretion within hepatocytes; and (3) post-hepatic (obstructive/cholestatic) — bile flow is physically or functionally obstructed, preventing excretion. Neonatal jaundice is a distinct, highly prevalent entity: physiologic hyperbilirubinemia affects up to 60% of term neonates in the first week of life due to fetal hemoglobin breakdown, immature hepatic conjugation capacity, and enterohepatic recirculation (AAP Clinical Practice Guideline on Hyperbilirubinemia).

For coding and CDI purposes, precise documentation of jaundice type, etiology, bilirubin fractionation (total vs. direct/conjugated), severity, and treatment threshold is required to support appropriate code selection across neonatal, pediatric, adult, and obstetric populations.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Clinical presentation varies by age group and etiology. Key findings that support documentation specificity include:

• Icteric sclerae — often the earliest visible sign in adults (detectable at bilirubin ~2 mg/dL); in neonates, assessed by blanching the skin under a light source
• Yellow skin discoloration — cephalocaudal progression in neonates (Kramer zones); generalized in adults
• Dark urine (bilirubinuria) — tea-colored or cola-colored urine indicates conjugated (direct) hyperbilirubinemia (obstructive or hepatocellular); absent in pure unconjugated hyperbilirubinemia
• Pale/clay-colored stools (acholia) — hallmark of biliary obstruction; indicates absence of bilirubin in stool
• Pruritus — prominent in cholestatic conditions (bile acid accumulation); characteristic of intrahepatic cholestasis of pregnancy
• Hepatomegaly / splenomegaly — hepatosplenomegaly suggests hemolytic anemia or portal hypertension
• Neonatal-specific: poor feeding, lethargy, high-pitched cry, hypotonia — early warning signs of acute bilirubin encephalopathy; opisthotonus and seizures indicate advanced kernicterus
• Fever, right upper quadrant pain, and jaundice (Charcot's triad) — classic for choledocholithiasis with cholangitis
• Ascites, spider angiomata, palmar erythema, caput medusae — signs of portal hypertension / cirrhotic hepatocellular cause

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

The following clinical indicators, when documented in the medical record, support specific and complete ICD-10-CM code assignment. CDI professionals should query when these indicators are present but the specific etiology or type has not been documented by the treating clinician.

🦴 Anatomy & Pathophysiology

Bilirubin Metabolism Pathway: Approximately 80% of bilirubin derives from senescent RBC hemoglobin catabolism in reticuloendothelial cells (spleen, liver, bone marrow). Heme oxygenase converts heme to biliverdin; biliverdin reductase converts biliverdin to unconjugated bilirubin. Unconjugated bilirubin is lipid-soluble, albumin-bound, and crosses the blood-brain barrier — making it neurotoxic at high levels (critical in neonates with kernicterus risk). The liver takes up unconjugated bilirubin via OATP transporters; UGT1A1 enzyme (encoded by the UGT1A1 gene) conjugates it to form bilirubin diglucuronide. Conjugated bilirubin is excreted into bile via MRP2 (ABCC2) transporters and passes into the small intestine. Intestinal bacteria reduce it to urobilinogen; most is excreted in stool (stercobilin — brown color), a small fraction reabsorbed and excreted in urine (StatPearls).

Neonatal physiology: Neonates have a higher RBC turnover rate (fetal hemoglobin transition), immature hepatic UGT1A1 activity, and enhanced enterohepatic recirculation (sterile gut, beta-glucuronidase activity). These factors combine to produce physiologic hyperbilirubinemia in 60% of term and 80% of preterm infants. Phototherapy converts unconjugated bilirubin to water-soluble photoisomers (lumirubin, Z-lumirubin) that can be excreted without conjugation (AAP 2004 Guideline; updated by AAP 2022 guidelines per Kemper et al., Pediatrics 2022).

Obstructive pathophysiology: Biliary obstruction (gallstones, strictures, malignancy) impairs excretion of conjugated bilirubin into the intestine. Conjugated bilirubin backs up into the bloodstream (conjugated hyperbilirubinemia), spills into urine (bilirubinuria/dark urine), and prevents stercobilin formation (pale stools). Cholestasis also triggers bile acid accumulation — responsible for severe pruritus and hepatocellular damage if prolonged.

Hepatocellular pathophysiology: In hepatocellular disease (hepatitis, cirrhosis, DILI), both unconjugated and conjugated bilirubin may accumulate due to impaired uptake, conjugation, and excretion. The pattern is typically mixed hyperbilirubinemia. Portal hypertension, coagulopathy (impaired clotting factor synthesis), hypoalbuminemia, and encephalopathy may accompany severe hepatocellular jaundice.

Kernicterus mechanism: When unconjugated bilirubin exceeds albumin-binding capacity (high bilirubin levels, low albumin, acidosis, or displacing drugs), free bilirubin crosses the BBB and deposits in the basal ganglia (globus pallidus, subthalamic nucleus), cerebellum, and hippocampus, causing oxidative damage and neuronal death. Sequelae include athetoid cerebral palsy, auditory neuropathy, gaze abnormalities, and cognitive impairment (StatPearls — Kernicterus).

💊 Medication Impact / Treatment

Phototherapy (neonatal): First-line treatment for neonatal hyperbilirubinemia. Conventional phototherapy uses blue-green light (460–490 nm wavelength) to convert unconjugated bilirubin to water-soluble photoisomers. Intensive/double phototherapy is used for high-risk neonates or rapidly rising bilirubin. The 2022 AAP guidelines provide updated risk-stratified Bhutani nomogram thresholds for initiating and escalating phototherapy based on gestational age, postnatal age (hours), and neurotoxicity risk factors (Kemper et al., Pediatrics 2022). Home phototherapy (HCPCS E0202) may be used in selected low-risk infants. Phototherapy CPT 94780 was removed from CPT; billing is via appropriate E/M codes plus facility charges.

Exchange transfusion: Reserved for severe/refractory hyperbilirubinemia or acute bilirubin encephalopathy. Double-volume exchange transfusion removes bilirubin and sensitized RBCs and provides albumin. Used in HDN (P55.x) with kernicterus risk.

Intravenous immunoglobulin (IVIG): Used adjunctively in HDN (ABO/Rh isoimmunization) to reduce hemolysis and avoid exchange transfusion. Document IVIG use and indication clearly for coding and coverage purposes.

Ursodeoxycholic acid (UDCA / Ursodiol): Treatment for intrahepatic cholestasis of pregnancy (O26.6x) and primary biliary cholangitis. Reduces bile acid toxicity and pruritus. May be used in inspissated bile syndrome neonatally.

Cholestyramine: Bile acid sequestrant; used for cholestatic pruritus management in adults (PSC, PBC, ICP).

Drugs that may precipitate or worsen jaundice (DILI — K71.x): Isoniazid, rifampin, amoxicillin-clavulanate, statins, acetaminophen (toxic hepatitis at high doses), anabolic steroids, oral contraceptives, antifungals (azoles), methotrexate. Document specific offending agent when drug-induced liver injury (K71.x) is diagnosed.

Drugs that displace bilirubin from albumin (neonatal risk): Sulfonamides, ceftriaxone (avoid in neonates with hyperbilirubinemia), ibuprofen; these increase free bilirubin and kernicterus risk. Document any such drug use in the neonatal record.

Tin-mesoporphyrin (SnMP): Investigational heme oxygenase inhibitor to reduce bilirubin production; not yet FDA approved for clinical use in neonates.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides